Dr. Daniel SW Tan
Medical Oncology
Senior Consultant
National Cancer Centre Singapore
Clinician-Scientist Fellow, The Genome Institute
Singapore
Why is whole genome sequencing with NGS uniquely applicable to patients with NSCLC?
Why is whole genome sequencing with NGS uniquely applicable to patients with NSCLC?
How has the clinical trial landscape for precision oncology changed under the influence of NGS?
How has the clinical trial landscape for precision oncology changed under the influence of NGS?
Are all NGS platforms created equally? How are they different?
Are all NGS platforms created equally? How are they different?
What specific and actionable molecular derangements are identified by NGS to guide targeted therapy?
What specific and actionable molecular derangements are identified by NGS to guide targeted therapy?
When is the ideal timing for obtaining whole exome sequencing? Is the timing strategy tumor dependent?
What are the possible limitations of NGS and what is the importance of working with a molecular tumor board?